. Author manuscript; available in PMC: 2013 May 2.

Published in final edited form as: J Thorac Oncol. 2010 May;5(5):713–718. doi: 10.1097/JTO.0b013e3181d7776d

TABLE 3.

Antitumor Activity^a

	Arm A, n (%)	Arm B, n (%)
Overall response rates (n = 76)^b
CR	2/40 (5)	1/33 (3)
PR	19/40 (47)^c	10/33 (30)^c
SD	12/40 (30)	9/33 (27)
PD	7/40 (18)	13/33 (39)
Not evaluable	2	1

Antitumor activity assessed by PET EORTC criteria when available and by CT RECIST criteria 1.0 when no PET was available.

Six patients did not get repeat imaging: Three patients (one in Arm A and two in Arm B) died before repeat imaging and were assigned as PD. One patient in Arm A went to surgery during cycle 1, and one patient was taken off trial for toxicity without progression. In Arm B, one patient was removed for toxicity without progression.

95% confidence interval for overall response (CR + PR) 36–68% and 18–52% for Arm A and B, respectively.

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PET, positron emission tomography; EORTC, European Organization for Research and Treatment of Cancer.